Biomarin Pharmaceutical Inc.

Repligen Corporation

W. R. Grace Co.-conn.

The United States of America As Represented by the Department of Health

James R Rusche

Norton P Peet

Vincent Jacques

Jasbir Singh

Allen T Hopper

Flossie Wong-Staal

James Neil Pryor

Feng Gu

Vincent P Pigiet

Jay F Rappaport

James M Bogdanor

James Ronald Peyser

Jundong Zhang

Thomas Pauly

Dennis McCreary

Surya Kiran Chodavarapu

John Bonham-Carter

Barbara J Schuster

Shashi Kiran Kudugunti

WengLong Roy Lin

Andrew Cooper

Methods and systems of harvesting a cell product from a cell culture by culturing cells in a fluid medium until the cells have produced a cell product at a harvest concentration are disclosed. The cells are cultured in a cell culture system including a bioreactor connected to an ATF device. The methods include draining fluid medium from the bioreactor through the outlet and the ATF device until the bioreactor volume reaches a predetermined volume, and the ATF column yields at an ATF outlet a liquid containing cell product and passes fluid medium with a concentration of cell product that is lower than the harvest concentration back into the bioreactor, extracting the liquid containing cell product from the ATF outlet, refilling the bioreactor with sterile phosphate buffered saline or fluid medium without any cell product, and repeating steps until a desired amount of cell product has been removed.

Alternating tangential flow rapid harvesting

Chromatography media and devices containing chromatography media are disclosed. Methods of making chromatography devices and methods of using chromatography devices containing the chromatography media are also disclosed.

Affinity chromatography media and chromatography devices

This invention relates to generally inhibiting histone deacetylase ('HDAC') enzymes (e.g., HDAC1, HDAC2, and HDAC3).

Histone deacetylase inhibitors

Disclosed herein are compounds of formula (I), and methods of inhibiting histone deacetylase ('HDAC') enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I). 

HDAC inhibitors

The compounds provided herein are phenyl analine amides and are useful for inhibiting histone deacteylase ('HDAC') enzymes, such as HDAC1, HDAC2, and HDAC3.

This invention relates to compounds of Formula (I) wherein Cy, L, Y, R, L, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions. 

Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors

This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).

This invention relates to compounds of Formula (I) wherein Cy, L, Y, R, L, and Arare defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions. 

This invention relates to generally inhibiting histone deacetylase ('HDAC') enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I), wherein the substituents are as defined herein.

Growing community of inventors

Framingham, MA, United States of America

James R Rusche